CEA and CA 15-3 during disease progression in metastatic breast cancer;CEA und CA15-3 beim fortgeschrittenen mammakarzinom

LaboratoriumsMedizin

Volumn 31, Issue 2, 2007, Pages 70-75

  Laessig, Dorit ^a   Nagel, Dorothea ^a   Heinemann, Volker ^a   Untch, Michael ^a   Kahlert, Steffen ^a   Bauerfeind, Ingo ^a   Stieber, Petra ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cancer antigen (CA) 15 3; Carcino embyronic antigen (CEA); Metastatic breast cancer; Tumor marker

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DESCRIPTIVE RESEARCH; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; PATIENT ASSESSMENT; SENSITIVITY ANALYSIS;

EID: 34247093671     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/JLM.2007.014     Document Type: Article

References (21)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Lamerz R, Stieber P, Fateh-Moghadam A. Serum marker combinations in human breast cancer wreviewx. In Vivo 1993;7:607-13.
3. Vizcarra E, Lluch A, Cibrian R, Jarque F, Alberola V, Belloch V, et al. Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis. Breast Cancer Res Treat 1996;37:209-16.
4. Untch M, Sauer H, Stieber P. Tumor Markers in Breast Cancer. J Lab Med 2001;25:343-52.
5. American Society of Clinical Oncology Tumor Marker Expert Panel. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-77.
6. Jaeger W, Eibner K, Loffler B, Gleixner S, Kramer S. Serial CEA and CA 15-3 measurements during follow-up of breast cancer patients. Anticancer Res 2000;20:5179-82.
7. Molina R, Zanon G, Filella X, Moreno F, Jo J, Daniels M, et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 1995;36:41-8.
8. Nicolini A, Colombini C, Luciani L, Carpi A, Giuliani L. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer 1991;64:154-8.
9. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer - European Group on Tumor Markers recommendations. Tumour Biol 2005;26:281-93.
10. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Munoz M, et al. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat 1998;51:109-19.
11. van Dalen A. Significance of cytokeratin markers TPA, TPA (cyk), TPS and CYFRA 21.1 in metastatic disease. Anticancer Res 1996;16:2345-9.
12. Gion M, Mione R, Nascimben O, Valsecchi M, Gatti C, Leon A, et al. The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases. Br J Cancer 1991;63:809-13.
13. Robertson JF, Pearson D, Price MR, Selby C, Pearson J, Blamey RW, et al. Prospective assessment of the role of five tumour markers in breast cancer. Cancer Immunol Immunother 1991;33:403-10.
14. Ammon A, Eiffert H, Alhusen R, Weber M, Rumelin B, Groh E, et al. Mucin-like carcinoma-associated antigen: sensitivity and specificity in metastatic breast cancer. Onkologie 1990;13:210-4.
15. Ammon A, Eiffert H, Weber M, Alhusen R, Beyer J. Tumor-marker in der Verlaufskontrolle des metastasierten Mammacarcinoms-Ein Vergleich der tumorassoziierten Antigene CEA, CA 15-3, MCA, CA 12-5. In Vivo Diagnostica Special 1991;2:14.
16. Colomer R, Ruibal A, Genolla J, Rubio D, Del Campo HM, Bodi R, et al. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat 1989;13:123-33.
17. Geraghty JG, Coveney EC, Sherry F, O'Higgins NJ, Duffy MJ. CA 15-3 in patients with locoregional and metastatic breast carcinoma. Cancer 1992;70:2831-4.
18. Berruti A, Tampellini M, Torta M, Buniva T, Gorzegno G, Dogliotti L. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer 1994;30A:2082-4.
19. al-Jarallah MA, Behbehani AE, el-Nass SA, Temim L, Ebraheem AK, Ali MA, et al. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. Eur J Surg Oncol 1993;19:74-9.
20. Safi F, Kohler I, Rottinger E, Beger H. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Cancer 1991;68:574-82.
21. Ebeling FG, Stieber P, Untch M, Nagel D, Konecny GE, Schmitt UM, et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer 2002;86:1217-22.